Beckman Coulter, Brea, Calif, has received FDA 510(k) clearance for its PK7400 Automated Microplate System and the system’s reagents have completed FDA approval. Designed for use in blood donor and plasma centers, as well as large reference laboratories, the PK7400 Automated Microplate System offers high throughput and is now available in countries across Europe, Canada, and the United States. According to the AABB (formerly the American Association of Blood Banks), an estimated 33,000 units of blood are needed each day to meet patient need. However, the organization also stated, more than 4,000 blood donation events have been canceled due to the covid-19 pandemic. “Blood donation is critically important under normal circumstances, as one donation can save up to three lives, but even more so now,” says Shamiram R. Feinglass, MD, MPH, chief medical officer, Beckman Coulter. “During this challenging time, those that are feeling well and healthy should continue to make and keep donation appointments to help ensure life-saving blood is available for patients that need it most.” The PK7400 Automated Microplate System:

  • Processes up to 300 samples per hour with a maximum of 12 tests per sample
  • Includes proprietary liquid and ready-to-use reagents
  • Provides the end user the ability to test multiple assays in a single batch without decreasing the throughput
  • Includes an assay menu with ABO blood grouping, Rh typing, weak D testing, Rh-Kell phenotyping, as well as syphilis and CMV qualitative screening

For more information on the PK7400, visit Beckman Coulter.